Scholarlink

Purpose <p>The aim is to evaluate treatment outcomes and prognostic factors in patients with thymic epithelial tumor (TET) treated with radiotherapy (RT).</p> Methods <p>Sixty-four patients were treated between 2000 and 2023. The median age was 52&#xa0;years (20–83), and 81% of underwent R0 resection. The stage&#xa0;(s) distribution for&#xa0;I, II, III, and&#xa0;IV were 5%, 61%, 26%, and 8% by Masaoka-Koga and 63%, 11%, 17%, and 9% by TNM, respectively. WHO types&#xa0;A/AB/B/C and thymic neuroendocrine tumors were seen in 5%, 22%, 64%, 6%, and 3% of patients, respectively. The median RT dose was 5040 cGy (1620–6596). Survival was calculated from the beginning of RT.</p> Results <p>The median follow-up was 70&#xa0;months (1.5–268). The median time to recurrence was 30&#xa0;months (6.5–106), seen in 23% of patients. Mean overall (OS), progression-free survival (PFS) and 5‑year local control were 141, 138&#xa0;months, and 82.4%, respectively. In univariate analysis, the presence of organ invasion and TNM stage were significant as new prognostic factors for survival (<i>p</i> &lt; 0.05). In multivariate analysis, the high-risk group (B2/B3/C) and another surgical center (<i>p</i> &lt; 0.05) for OS, and KPS ≤ 80, thymic carcinoma, and Masaoka-Koga sIII-IV (<i>p</i> &lt; 0.05) for PFS were identified as unfavorable prognostic factors.</p> Conclusion <p>Recurrence in TET can occur over a&#xa0;longer period. In this study, 5‑year local control of 82.4% was achieved. The prognostic importance of KPS, histology, Masaoka-Koga stage, risk group, and surgical center was demonstrated. Advances in the diagnosis, staging, and treatment of TET will enable more personalized treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thymic tumors: radiotherapy experience for single institute

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月23日

查看全文
  • Sureyya Sarihan,
  • Aybuke Tugce Metin,
  • Ahmet Sami Bayram,
  • Huseyin Melek

摘要

Purpose

The aim is to evaluate treatment outcomes and prognostic factors in patients with thymic epithelial tumor (TET) treated with radiotherapy (RT).

Methods

Sixty-four patients were treated between 2000 and 2023. The median age was 52 years (20–83), and 81% of underwent R0 resection. The stage (s) distribution for I, II, III, and IV were 5%, 61%, 26%, and 8% by Masaoka-Koga and 63%, 11%, 17%, and 9% by TNM, respectively. WHO types A/AB/B/C and thymic neuroendocrine tumors were seen in 5%, 22%, 64%, 6%, and 3% of patients, respectively. The median RT dose was 5040 cGy (1620–6596). Survival was calculated from the beginning of RT.

Results

The median follow-up was 70 months (1.5–268). The median time to recurrence was 30 months (6.5–106), seen in 23% of patients. Mean overall (OS), progression-free survival (PFS) and 5‑year local control were 141, 138 months, and 82.4%, respectively. In univariate analysis, the presence of organ invasion and TNM stage were significant as new prognostic factors for survival (p < 0.05). In multivariate analysis, the high-risk group (B2/B3/C) and another surgical center (p < 0.05) for OS, and KPS ≤ 80, thymic carcinoma, and Masaoka-Koga sIII-IV (p < 0.05) for PFS were identified as unfavorable prognostic factors.

Conclusion

Recurrence in TET can occur over a longer period. In this study, 5‑year local control of 82.4% was achieved. The prognostic importance of KPS, histology, Masaoka-Koga stage, risk group, and surgical center was demonstrated. Advances in the diagnosis, staging, and treatment of TET will enable more personalized treatment.